Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey

Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong prophylactic treatment, typically with recombinant FVIII. In recent years, drugs with extended half-lives have become available, including damoctocog alfa pegol (Bayer S.p.A.). The clinical efficacy and...

书目详细资料
主要作者:	Ezio Zanon
格式:	文件
语言:	English
出版:	MDPI AG 2023-08-01
丛编:	Pharmaceuticals
主题:	Hemophilia A coagulation factor VIII deficiency prophylaxis damoctocog alfa pegol
在线阅读:	https://www.mdpi.com/1424-8247/16/9/1195

相似书籍

Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy
由: Federica Demma, et al.
出版: (2022-06-01)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
由: Steven R. Lentz, et al.
出版: (2022-02-01)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
由: Napolitano M, et al.
出版: (2021-01-01)

Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis
由: Chonlatis Srichumpuang, et al.
出版: (2024-03-01)

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
由: Eichler H, et al.
出版: (2023-11-01)

Treatment With Efmoroctocog Alfa (Elocta®) in Hemophilia: A Case Series
由: Ezio Zanon, et al.
出版: (2020-10-01)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
由: Davide Matino, et al.
出版: (2022-03-01)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
由: Kearney S, et al.
出版: (2019-04-01)

Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
由: Ilaria Nichele, et al.
出版: (2024-04-01)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
由: Saunya Dover, et al.
出版: (2020-02-01)

Clinical and Laboratory Approaches to Hemophilia A
由: Hassan Mansouritorghabeh
出版: (2015-05-01)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
由: Anthony K. Chan, et al.
出版: (2020-10-01)

Prophylaxis in Hemophilia
由: Júlia Plentz Portich, et al.
出版: (2023-05-01)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
由: Maria Sol Cruz, et al.
出版: (2021-05-01)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
由: Johnny Mahlangu, et al.
出版: (2021-08-01)

Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A
由: Hemophilia Treatment Center Collaborative Network of China
出版: (2022-10-01)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
由: Kenet G, et al.
出版: (2023-06-01)

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
由: Yang R, et al.
出版: (2020-11-01)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
由: Karla Rener, et al.
出版: (2023-11-01)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
由: Michael U. Callaghan, et al.
出版: (2022-08-01)

Immunogenicity of Current and New Therapies for Hemophilia A
由: Alessandra N. L. Prezotti, et al.
出版: (2022-07-01)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
由: Tine M.H.J. Goedhart, et al.
出版: (2022-01-01)

A Rare Case of Acquired Hemophilia A in Adolescents and Young Adults
由: Min Jeong Lee, et al.
出版: (2022-04-01)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
由: Masahiro Takeyama, et al.
出版: (2020-10-01)

Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India
由: Tulika Seth, et al.
出版: (2023-12-01)

Evaluation of the efficacy and safety of human coagulation factor Ⅷ in the treatment of hemophilia A patients
由: Ruyi CHEN, et al.
出版: (2022-12-01)

Acquired Hemophilia A with Gastrointestinal Bleeding
由: Narae Park, et al.
出版: (2020-01-01)

Efficacy and safety evaluation of plasma-derived human coagulation factor Ⅷ in patients with hemophilia A
由: Shumin LIANG, et al.
出版: (2023-09-01)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
由: Midori Shima
出版: (2020-05-01)

Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States
由: Wu Y, et al.
出版: (2022-09-01)

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages
由: Anne Schoenbrunn, et al.
出版: (2022-07-01)

Global coagulation assays in hemophilia A: A comparison to conventional assays
由: Saman Aghighi, et al.
出版: (2020-02-01)

Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia A
由: Prakas Kumar Mandal, et al.
出版: (2019-01-01)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
由: Renchi Yang, et al.
出版: (2022-02-01)

Flow Cytometry Evaluation of Blood-Cell-Bound Surface FVIII in Hemophilia A and Thrombosis
由: Anjud Al-Mohannadi, et al.
出版: (2025-01-01)

Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient
由: Vanessa Innao, et al.
出版: (2017-05-01)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
由: Jerome Teitel, et al.
出版: (2021-02-01)

MYOCARDIAL INFARCTION AND HEMOPHILIA
由: A. S. Galyavich, et al.
出版: (2016-03-01)

Short-term intermittent prophylaxis post-intracranial hemorrhage in children with hemophilia
由: Novie Amelia Chozie, et al.
出版: (2022-05-01)

Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa
由: Matteo Nicola Dario Di Minno, et al.
出版: (2020-04-01)